339 related articles for article (PubMed ID: 30226780)
21. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
[TBL] [Abstract][Full Text] [Related]
22. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Reilly EB; Phillips AC; Buchanan FG; Kingsbury G; Zhang Y; Meulbroek JA; Cole TB; DeVries PJ; Falls HD; Beam C; Gu J; Digiammarino EL; Palma JP; Donawho CK; Goodwin NC; Scott AM
Mol Cancer Ther; 2015 May; 14(5):1141-51. PubMed ID: 25731184
[TBL] [Abstract][Full Text] [Related]
23. In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab.
Caratelli S; Arriga R; Sconocchia T; Ottaviani A; Lanzilli G; Pastore D; Cenciarelli C; Venditti A; Del Principe MI; Lauro D; Landoni E; Du H; Savoldo B; Ferrone S; Dotti G; Sconocchia G
Int J Cancer; 2020 Jan; 146(1):236-247. PubMed ID: 31479522
[TBL] [Abstract][Full Text] [Related]
24. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X
Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333
[TBL] [Abstract][Full Text] [Related]
25. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977
[TBL] [Abstract][Full Text] [Related]
26. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
27. Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates.
Huang R; Sheng Y; Wei D; Lu W; Xu Z; Chen H; Jiang B
Bioorg Med Chem; 2020 Dec; 28(23):115793. PubMed ID: 33039798
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
29. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.
Wu S; Deng C; Zhang C; Xiong J; Gu X; Wang Z; Tu J; Xie J
Clin Transl Oncol; 2021 Aug; 23(8):1549-1560. PubMed ID: 33474678
[TBL] [Abstract][Full Text] [Related]
30. Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy.
Tseng SH; Chou MY; Chu IM
Int J Nanomedicine; 2015; 10():3663-85. PubMed ID: 26056447
[TBL] [Abstract][Full Text] [Related]
31. Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
Hu WJ; Liu J; Zhong LK; Wang J
Biomed Pharmacother; 2018 Jun; 102():681-688. PubMed ID: 29604587
[TBL] [Abstract][Full Text] [Related]
32. A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan.
Qiu W; Zhang C; Wang S; Yu X; Wang Q; Zeng D; Du P; Ma J; Zheng Y; Pang B; Yu Y; Long F; Pang X; Sun Z
J Immunol Res; 2019; 2019():3017360. PubMed ID: 30733972
[TBL] [Abstract][Full Text] [Related]
33. Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.
Schönfeld K; Herbener P; Zuber C; Häder T; Bernöster K; Uherek C; Schüttrumpf J
Pharm Res; 2018 Apr; 35(6):118. PubMed ID: 29666962
[TBL] [Abstract][Full Text] [Related]
34. Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity.
Ho ECH; Qiu R; Miller E; Bilotta MT; FitzGerald D; Antignani A
Biomed Pharmacother; 2023 Jan; 157():114047. PubMed ID: 36459711
[TBL] [Abstract][Full Text] [Related]
35. Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis.
Takahashi JI; Nakamura S; Onuma I; Zhou Y; Yokoyama S; Sakurai H
Sci Rep; 2022 Jul; 12(1):11561. PubMed ID: 35798841
[TBL] [Abstract][Full Text] [Related]
36. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
37. Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.
He K; Xu J; Liang J; Jiang J; Tang M; Ye X; Zhang Z; Zhang L; Fu B; Li Y; Bai C; Zhang L; Tao W
Mol Cancer Ther; 2019 Jun; 18(6):1104-1114. PubMed ID: 30962319
[TBL] [Abstract][Full Text] [Related]
38. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.
Phillips AC; Boghaert ER; Vaidya KS; Mitten MJ; Norvell S; Falls HD; DeVries PJ; Cheng D; Meulbroek JA; Buchanan FG; McKay LM; Goodwin NC; Reilly EB
Mol Cancer Ther; 2016 Apr; 15(4):661-9. PubMed ID: 26846818
[TBL] [Abstract][Full Text] [Related]
39. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
[TBL] [Abstract][Full Text] [Related]
40. Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen.
Nagaya T; Sato K; Harada T; Nakamura Y; Choyke PL; Kobayashi H
PLoS One; 2015; 10(8):e0136829. PubMed ID: 26313651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]